ArticleNature2026
Evolution and heterogeneity of lethal metastatic bladder cancer subtypes.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
Pushpa Itagi *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Samantha L Schuster *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Sonali AroraHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6661-3024
Thomas W PerssePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jennifer A WatersHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Michael YangPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Alan MinPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Pooja ChandraPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0009-0001-6130-8792
Mohamed AdilPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Patricia C GalipeauPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7961-7430
Dmytro RudoyHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Allie S KreitmanDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-0390-5425
Yixin LinPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0009-0009-7449-3155
Minjeong KoPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Erolcan SayarHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3922-5683
Robert D PattonPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2159-1199
Lori KollathDepartment of Urology, University of Washington, Seattle, WA, USA.
Abby MeisDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0009-0004-2632-2603
Samuel LindergrenDepartment of Urology, University of Washington, Seattle, WA, USA.
Nathan JiDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0009-0001-7757-370X
Khursheed AliDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-1578-1781
Hrishi VenkateshImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Cynthia L WladykaHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
A Patrick McDeedPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Claire B MillsHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Manasvita VashisthPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jin Yeong KimHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Rosa NadalDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Jessica E HawleyDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Todd A YezefskiDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2518-1680
Sarah P PsutkaDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-4207-7490
John L GoreDepartment of Urology, University of Washington, Seattle, WA, USA.
Daniel W LinPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Peter S NelsonPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-5451-5726
Heather H ChengDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Michael T SchweizerDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Lawrence FongImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6428-428X
John K LeeHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6570-2180
Evan Y YuDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9244-3807
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, WA, USA.
Petros GrivasDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-3965-3394
Robert B MontgomeryDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Jonathan L WrightDepartment of Urology, University of Washington, Seattle, WA, USA.
Michael C HaffnerHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Funda Vakar-LopezDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Omar Y MianHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. omian@fredhutch.org.ORCID http://orcid.org/0000-0002-8133-8120
Hung-Ming LamDepartment of Urology, University of Washington, Seattle, WA, USA. minglam@uw.edu.ORCID http://orcid.org/0000-0001-8921-6091
Andrew C HsiehHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ahsieh@fredhutch.org.ORCID http://orcid.org/0000-0002-0897-1050
Gavin HaPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. gha@fredhutch.org.ORCID http://orcid.org/0000-0001-7578-7272
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histological variation is a prognostic feature of metastatic urothelial cancer
Identifiers
PMID
42749807What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.